FDA Grants Virax Biolabs Emergency Use Authorization for Covid-19 Test
By Dean Seal
Virax Biolabs Group Ltd. has received emergency use
authorization from the Food and Drug Administration for its
over-the-counter Covid-19 rapid antigen test.
Chief Executive James Foster said Tuesday that the authorization
allows the company to enter the U.S. market and that Virax has
manufacturing capacity, through a partner, for up to 2 million
tests a day.
Tests are ready for sale in the U.S., the biotech company said,
noting it is also seeking approval for another rapid antigen test
to be distributed in Canada.
Write to Dean Seal at firstname.lastname@example.org
(END) Dow Jones Newswires
December 06, 2022 08:25 ET (13:25 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.